Sareum Holdings plc (AIM:SAR)

London flag London · Delayed Price · Currency is GBP · Price in GBX
16.26
-1.24 (-7.09%)
May 13, 2025, 10:19 AM GMT+1
-43.93%
Market Cap 23.52M
Revenue (ttm) n/a
Net Income (ttm) -2.83M
Shares Out 134.41M
EPS (ttm) -0.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 115,807
Average Volume 360,261
Open 17.98
Previous Close 17.50
Day's Range 16.26 - 17.98
52-Week Range 11.00 - 52.50
Beta -1.75
RSI 50.12
Earnings Date Jun 23, 2025

About Sareum Holdings

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company’s lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also involves in developing SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical stage for cancer and cancer-immunotherapy applications; and SRA737, a clinical-stage oral, selective Checkpoint kinase 1 inhibitor, which h... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 5
Stock Exchange London Stock Exchange AIM
Ticker Symbol SAR
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.